TMX deal to buy Cboe exchanges in Canada and Australia raises questions about competition

TMX Group will pay US$300 million to acquire Cboe Global Markets’ Canadian and Australian assets, a move that could strengthen TMX’s dominance in Canadian capital markets and expand its international listings footprint. The deal may draw competition review scrutiny, but analysts called it positive for TMX, citing expected synergies and lower execution, connectivity, and data costs.

Analysis

The immediate winner is TMX’s economics, but the larger second-order beneficiary is the Canadian exchange duopoly as a whole. By absorbing a mid-tier competitor and potentially ring-fencing ETFs from corporate listings, TMX can push the industry toward higher fixed-cost density: lower unit connectivity cost for itself, but also higher switching friction for participants. That typically widens the moat around the incumbent cash equity franchise, even if headline anti-competition scrutiny creates a near-term overhang.

The main loser is CBOE’s remaining growth optionality outside the U.S. The market is likely to treat this as a strategic retreat from non-core listings, which makes international expansion less credible and weakens the “global diversification” narrative for a multiple that already leans on higher-growth market structure assets. More subtly, ATS venues and smaller fintech routing providers may see a temporary burst of interest as clients look for residual competitive pressure, but if TMX successfully integrates venue functionality, those alternatives become more dependent on regulatory remedies than on organic share gains.

The key risk is timing mismatch: the commercial upside could show up quickly via cost rationalization, while the antitrust process may drag for months and force concessions that dilute the strategic value. If regulators require divestitures, separate ETF venues, or access-price commitments, TMX’s operating leverage thesis gets weaker but the competitive landscape could actually improve for alternative venues. If approval comes through with few conditions, the market should re-rate TMX on a higher-quality, lower-friction revenue base, while CBOE should remain under pressure as investors discount the probability of additional asset sales.

The contrarian take is that this may be better for market structure than the headlines suggest. Canadian ETF trading has enough latent liquidity to support a specialized venue, and the acquisition could catalyze a real challenger if the CSE or another ATS moves quickly on a dedicated ETF listing/trading product. In that scenario, TMX wins on cost but loses some price power, and the long-term competitive equilibrium could be more balanced than the immediate reaction implies.

Key Decisions for Investors

• Go long TMX on pullbacks over the next 2-8 weeks, targeting approval optionality and synergy upside; use a tight stop on any Competition Bureau signals of material remedies, as that is the main catalyst that can compress the deal premium.
• Short CBOE vs. long a U.S. market-infrastructure peer basket for 1-3 months; the Canadian/Australian asset sale removes a growth lever and should modestly weaken CBOE’s non-core valuation narrative.
• If options liquidity is available, buy TMX call spreads 3-6 months out to capture approval plus integration upside while capping premium paid; this is cleaner than outright stock if regulatory timing is uncertain.
• Speculative relative-value long CSE / short TMX only if the ETF venue thesis gains traction in industry consultations; this is a high-risk catalyst trade, but the upside is meaningful if Canada ends up with a credible dedicated ETF competitor.
• Avoid chasing CBOE short aggressively until the deal structure and regulatory remedies are clearer; the stock can be less sensitive to the asset sale than expected if the market views it as disciplined capital recycling.